ArticleOncoimmunology
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 51 citations in OpenAlex.
- B7-H6/NKp30 Axis in Melanoma: Translational Rationale, Evidence Gaps, and Therapeutic Considerations.Biomolecules · 2026Review
- NKp30: A Key Membrane Molecule in the Fight Against Cancer and Infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Enhanced antileukemic effect of NKp30b isoform of donor-derived NK cells infused after HLA-haploidentical allogeneic hematopoietic cell transplantation in high-risk AML and MDS.Bone marrow transplantation · 2025Article
- Senescent Tumoral HLA-E Reshapes Microenvironment through Impairing NK Cell-Dendritic Cell-T Cell Network in Malignant Pleural Effusion from Lung Cancer.International journal of biological sciences · 2025Article
- Gastrointestinal Stromal Tumors (GISTs) in Pediatric Patients: A Case Report and Literature Review.Children (Basel, Switzerland) · 2024Review
- Natural Killer cells at the frontline in the fight against cancer.Cell death & disease · 2024Review
- Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies.Frontiers in oncology · 2024Review
- Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses.Clinical and experimental medicine · 2023Article
- Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.Molecular cancer · 2023Review
- Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.Frontiers in immunology · 2022Review
- The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.International journal of molecular sciences · 2021Review
- Review
- Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives.International journal of molecular sciences · 2021Review
- Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.Cancers · 2021Review
- Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.International journal of molecular sciences · 2021Article
- Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer.Frontiers in cell and developmental biology · 2021Review
- Article
- NKp30 - A prospective target for new cancer immunotherapy strategies.British journal of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 17 institutions in 2 countries.
Sylvie RusakiewiczGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France.
Aurélie PerierGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France.
Michaela SemeraroGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France; Department of Pediatric Oncology, GRCC, Villejuif, France.
Jonathan M PittGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France.
Elke Pogge von StrandmannDepartment of Internal Medicine I, University Hospital of Cologne , Cologne, Germany.
Katrin S ReinersDepartment of Internal Medicine I, University Hospital of Cologne , Cologne, Germany.
Sandrine AspeslaghGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France; Drug Development Department (DITEP), GRCC, Villejuif, France.
Christelle PipéroglouHôpital de la Conception, Assistance Publique-Hôpitaux de Marseille , Marseille, France.
Frédéric VélyHôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France; INSERM, U1104, Centre d'Immunologie de Marseille-Luminy, Marseille, France; CNRS, UMR7280, Marseille, France.
Alexandre IvagnesGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France.
Sarah JegouGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France.
Niels HalamaHamamatsu Tissue Imaging and Analysis Center (TIGA), BIOQUANT, Heidelberg, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Loic ChaigneauDepartment of Medical Oncology, Centre Hospitalier Universitaire Jean Minjoz , Besançon, France.
Pierre ValidireDepartment of Pathology, Institut Mutualiste Montsouris, Paris, France; Department of Medical Oncology, Sarcoma, Institut Mutualiste Montsouris, Paris, France.
Christos ChristidisDepartment of Medical Oncology, Sarcoma, Institut Mutualiste Montsouris, Paris, France; Department of Surgery, Institut Mutualiste Montsouris, University of Paris Descartes 5, Paris, France.
Thierry PerniceniDepartment of Medical Oncology, Sarcoma, Institut Mutualiste Montsouris , Paris, France.
Bruno LandiDepartment of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, University of Paris Descartes 5 , Paris, France.
Anne BergerDepartment of Surgery, Georges Pompidou European Hospital, University of Paris Descartes , Paris, France.
Nicolas IsambertDepartment of Medical Oncology, Centre Georges-François Leclerc , Dijon, France.
Julien DomontGustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Medicine, Sarcoma committee, GRCC, Villejuif, France.
Sylvie BonvalotGustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Medicine, Sarcoma committee, GRCC, Villejuif, France; Department of Surgery, GRCC, Villejuif, France.
Philippe TerrierGustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Medicine, Sarcoma committee, GRCC, Villejuif, France; Department of Pathology, GRCC, Villejuif, France; Center of Biological Resources, GRCC, Villejuif, France.
Julien AdamGustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Pathology, GRCC, Villejuif, France; Center of Biological Resources, GRCC, Villejuif, France.
Jean-Michel CoindreDepartment of Pathology, Institut Bergonié , Bordeaux, France.
Jean-François EmileDepartment of Pathology, EA4340, Hôpital Ambroise Paré , Boulogne, France.
Vichnou Poirier-ColameGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France.
Kariman ChabaEquipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
Benedita RochaINSERM, U1020, Paris, France; Faculté de Médecine René Descartes, Paris, France.
Anne CaignardINSERM, U1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France.
Antoine ToubertINSERM, U1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France.
David EnotGustave Roussy Cancer Campus (GRCC), Villejuif, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; INSERM, U1138, Paris, France; Metabolomics and Cell Biology platforms, GRCC, Villejuif, France.
Joachim KochInstitute of Medical Microbiology and Hygiene, University of Mainz Medical Centre , Mainz, Germany.
Aurélien MarabelleGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France; Drug Development Department (DITEP), GRCC, Villejuif, France.
Marion LambertINSERM, U1149, Equipe "Immunité innée chez l'enfant", Hôpital Robert Debré , Paris, France.
Sophie Caillat-ZucmanINSERM, U1149, Equipe "Immunité innée chez l'enfant", Hôpital Robert Debré , Paris, France.
Serge LeyvrazDepartment of Oncology, University Hospital , Lausanne, Switzerland.
Christian AuclairApplied Biology and Pharmacology Laboratory, Ecole Normale Supèrieur of Cachan , Cachan, France.
Eric VivierINSERM, U1104, Centre d'Immunologie de Marseille-Luminy, Marseille, France; CNRS, UMR7280, Marseille, France; Aix Marseille Université, UM2, Marseille, France.
Alexander EggermontGustave Roussy Cancer Campus (GRCC) , Villejuif, France.
Christophe BorgINSERM 1098, University of Franche-Comté , Besançon, France.
Jean-Yves BlayDepartment of Medicine, Centre Léon Bérard & Université Claude Bernard Lyon I, DGOS-INCA SIRIC , Lyon, France.
Axel Le CesneGustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Medicine, Sarcoma committee, GRCC, Villejuif, France.
Olivier MirGustave Roussy Cancer Campus (GRCC), Villejuif, France; Department of Medicine, Sarcoma committee, GRCC, Villejuif, France.
Laurence ZitvogelGustave Roussy Cancer Campus (GRCC), Villejuif, France; INSERM, U1015, IGR, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France; University of Paris Sud XI, Villejuif, France.
Inserm · FRInstitut Gustave Roussy · FRUniversité Paris Cité · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FRInstitute Mutualiste Montsouris · FRUniversity Hospital Cologne · DEAssistance Publique Hôpitaux de Marseille · FRCentre Georges François Leclerc · FRCentre Hospitalier Universitaire de Besançon · FRÉcole Normale Supérieure Paris-Saclay · FRHeidelberg University · DEHôpital Ambroise-Paré · FRInstitut Bergonié · FRJohannes Gutenberg University Mainz · DEUniversité Claude Bernard Lyon 1 · FRUniversité Paris-Sud · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite effective targeted therapy acting on
Indexed as
B7-H6CancerGISTimmunityNK cellsNKp30/NCR3
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.